Clinical Trial Update: Vyne Completes Enrollment in Phase 2b Study of Repibresib (Formerly VYN201) for Nonsegmental Vitiligo
VYNE Therapeutics Inc. has completed enrollment in the Phase 2b trial evaluating VYN201 gel for the treatment of nonsegmental vitiligo. Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025. Additionally, the United States Adopted Names (USAN) Council has adopted “repibresib” as the non-proprietary name for the new chemical entity in VYN201. VYNE […]